Drug Interaction Report

Consumer information for this interaction is not currently available.

MONITOR: Coadministration with inhibitors of CYP450 2D6 may increase the plasma concentrations of topical sofpironium, which has been shown to be partially metabolized by the isoenzyme. In a pharmacokinetic study in patients with primary axillary hyperhidrosis, sofpironium systemic exposure (AUC) and peak plasma concentration (Cmax) increased approximately 2-fold following concomitant use with the potent CYP450 2D6 inhibitor paroxetine at a 20 mg oral dose. Clinical data for sofpironium use in combination with other less potent CYP450 2D6 inhibitors are not available.

MANAGEMENT: Caution is advised when sofpironium topical is used concurrently with CYP450 2D6 inhibitors. Patients should be more closely monitored for adverse effects such as blurred vision, urinary retention, difficulty controlling body temperature in warm environments, and dry mouth.

Alcohol can increase the nervous system side effects of fluvoxaMINE such as dizziness, drowsiness, and difficulty concentrating. Some people may also experience impairment in thinking and judgment. You should avoid or limit the use of alcohol while being treated with fluvoxaMINE. Do not use more than the recommended dose of fluvoxaMINE, and avoid activities requiring mental alertness such as driving or operating hazardous machinery until you know how the medication affects you. Talk to your doctor or pharmacist if you have any questions or concerns.